TOG Review (RCOG Journal)

MRCOG Part 2

Maternal Medicine

Peripartum cardiomyopathy

Key Statistics

  • LVEF <45% — Diagnostic echo criterion (ESC 2010)
  • 78% — Present within 4 months of birth
  • 50–80% — Recover LV function (LVEF ≥50%)

Don't-miss facts

  1. Diagnostic criterion: LVEF <45% on echo, end of pregnancy to 6 months postpartum, no other cause — make the diagnosis, don’t just exclude it

  2. MBRRACE 2019 red flags: tachypnoea, chest pain, persistent tachycardia, orthopnoea — always fully investigate

  3. In pregnancy avoid ACEi / ARB / MRA; use metoprolol + hydralazine/nitrate + loop diuretic + salt restriction; LMWH for anticoagulation

  4. Anticoagulate if LVEF ≤35% and/or on bromocriptine; continue anticoagulation 6–8 months postpartum

  5. Bromocriptine 2.5 mg od ≥1 week; if EF <25%: 2.5 mg bd ×2 weeks then 2.5 mg od ×6 weeks — always with anticoagulation

  6. Cardiogenic shock: levosimendan 0.1 µg/kg/min for 24 h preferred over catecholamines; IV nitrate only if systolic BP

110 mmHg; target SpO₂ >95%

  1. Third stage: slow oxytocin infusion; second line misoprostol/carboprost; never ergometrine or long-acting oxytocin analogues

  2. Contraception: IUD (fit in hospital, no antibiotic prophylaxis) or progestogen LARC; avoid combined hormonal contraception and barrier methods

Numbers to recall

78% present <4 months postpartum Ventricular arrhythmia 20% VTE 2.2–6.8% Recovery 50–80% (LVEF ≥50%)

Mortality ~10% Relapse 20% even after full recovery 50% deteriorate if persistent LV dysfunction

~5% need mechanical support/transplant

Abbreviation Key

  • PPCM — peripartum cardiomyopathy
  • ARB — angiotensin receptor blocker
  • ESC — European Society of Cardiology
  • ARNI — angiotensin receptor neprilysin inhibitor
  • MBRRACE — Mothers and Babies: Reducing Risk through Audits
  • MRA — mineralocorticoid receptor antagonist and Confidential Enquiries
  • BNP — brain natriuretic peptide
  • LVEF — left ventricular ejection fraction
  • NT-proBNP — N-terminal pro-brain natriuretic peptide
  • LVEDD — left ventricular end-diastolic diameter
  • sFlt-1 — soluble fms-like tyrosine kinase receptor 1
  • ACEi — angiotensin-converting enzyme inhibitor
  • LMWH — low-molecular-weight heparin

Source: Kulkarni A, Squire G, Hogrefe K, Osman MW. Peripartum cardiomyopathy. The Obstetrician & Gynaecologist 2021;23:278–289. doi:10.1111/tog.12770

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free